ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BMRN BioMarin Pharmaceutical Inc

66.39
0.73 (1.11%)
Pre Market
Last Updated: 09:39:15
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioMarin Pharmaceutical Inc NASDAQ:BMRN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.73 1.11% 66.39 60.00 67.95 252 09:39:15

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

29/08/2024 1:00pm

PR Newswire (US)


BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart


From Jun 2024 to Dec 2024

Click Here for more BioMarin Pharmaceutical Charts.

SAN RAFAEL, Calif., Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024, at 7:45 AM PT / 10:45 AM ET in New York, NY.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

About BioMarin

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:


Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-22nd-annual-morgan-stanley-global-healthcare-conference-on-thursday-september-5-at-745-am-pt--1045-am-et-in-new-york-ny-302233312.html

SOURCE BioMarin Pharmaceutical Inc.

Copyright 2024 PR Newswire

1 Year BioMarin Pharmaceutical Chart

1 Year BioMarin Pharmaceutical Chart

1 Month BioMarin Pharmaceutical Chart

1 Month BioMarin Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock